预约演示

更新于：2026-05-20

Albumin-Bound Paclitaxel

白蛋白结合型紫杉醇

更新于：2026-05-20

概要

基本信息

药物类型

化学药

别名

Nab-Paclitaxel、Nab-PTX、Paclitaxel Albumin Nanoparticles

+ [18]

靶点

Tubulin

作用方式

抑制剂

作用机制

微管蛋白抑制剂

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [8]

在研适应症

肿瘤转移性胰腺癌胰腺癌+ [41]

非在研适应症

大肠腺癌小肠腺癌腺鳞癌+ [115]

原研机构

石药集团有限公司

Abraxis BioScience, Inc.

在研机构

AstraZeneca PLCBristol-Myers Squibb Pharma EEIGHoffmann-La Roche, Inc.

+ [14]

非在研机构

Genentech, Inc.Roche Pharma AG

GSK Plc

+ [12]

权益机构

浙江海昶生物医药股份有限公司

BeOne Medicines Ltd.

科兴生物制药股份有限公司

+ [8]

最高研发阶段批准上市

首次获批日期

美国 (2005-01-07),

转移性乳腺癌

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C47H51NO14

InChIKeyRCINICONZNJXQF-MZXODVADSA-N

CAS号33069-62-4

关联

2,424

项与白蛋白结合型紫杉醇相关的临床试验

NCT06592664

/ Withdrawn临床1/2期

A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating a Single Intravenous Push Followed by a Continuous Infusion of Certepetide Over 4 Hours When Added to Standard of Care (SoC) Versus Two Intravenous Pushes of Certepetide When Added to SoC, Versus SoC Alone in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (FORTIFIDE)

The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma.
The main questions it aims to answer are:
* is the new drug plus standard treatment safe and tolerable
* is the new drug plus standard treatment more effective than standard treatment
Participants will:
* Visit the clinic three times every 28 days for treatment and tests
* Have CT or MRI scans every 8 weeks while on treatment

开始日期2030-01-01

申办/合作机构

Lisata Therapeutics, Inc.

NCT07253662

/ Recruiting临床1期

Phase I Trial of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Adenocarcinoma

Palliative systemic therapy is the standard treatment option for patients with pancreatic ductal adenocarcinoma (PDAC) and peritoneal metastasis (PM), who have a median overall survival of only 6-11 months and a serious adverse event (SAE) rate of >5%. Patients with peritoneal-only metastasis may demonstrate unique tumor biology with less potential for hematogenous and lymphatic spread, making them potential candidates for a regional approach directed at the peritoneum. PIPAC is a drug- delivery system that combines the pharmacokinetic advantages of low- dose intraperitoneal chemotherapy (high tumor tissue penetration with low systemic absorption/toxicity) with the principles of aerosolization (homogenous intraperitoneal distribution and deeper tissue penetration). PIPAC may offer a complimentary approach to maximize drug delivery to tumor implants, potentially improving quality of life and survival without significant additional morbidity. Several non-randomized studies have evaluated safety, feasibility, and efficacy of PIPAC with various intraperitoneal agents in a variety of tumor types. Very few patients with pancreatic cancer PM have been included in these studies and most have been treated with either PIPAC-oxaliplatin or doxorubicin/cisplatin. A recent phase 1 dose-escalation study included patients with ovarian, gastric, breast, and hepatopancreatobiliary malignancies. One patient with
pancreatic cancer was included in this study. The recommended phase 2 dose was 140 mg/m2, with guidance to decrease the dose to 112.5 mg/m2 in patients with hepatic impairment. Therefore, the dose utilized in this study is 112.5 mg/m2. This recommendation was based on concern for nab-paclitaxel hepatotoxicity, but there was no data presented to support this expert recommendation.
This study sets out to explore the role of PIPAC with nab-paclitaxel in combination with medical oncology choice standard of care therapy in this patient population.

开始日期2026-12-30

申办/合作机构

Northwell Health, Inc.

NCT07258147

/ Not yet recruiting临床2期IIT

Clinical Study on the Efficacy and Safety of Radiotherapy Combined With Immunotherapy and Chemotherapy for Pre-treated Patients With Small Cell Lung Cancer and Liver Metastases

This is clinical trial evaluating the safety and efficacy of radiotherapy combined with immunotherapy and chemotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC) and liver metastases.

开始日期2026-10-31

申办/合作机构

四川大学

100 项与白蛋白结合型紫杉醇相关的临床结果

登录后查看更多信息

100 项与白蛋白结合型紫杉醇相关的转化医学

登录后查看更多信息

100 项与白蛋白结合型紫杉醇相关的专利（医药）

登录后查看更多信息

7,738

项与白蛋白结合型紫杉醇相关的文献（医药）

2026-12-31·Future Science OA

Clinical efficacy of 2-week and 3-week albumin-bound paclitaxel therapy for advanced pancreatic cancer

Article

作者: Su, Zhimin ; Li, Zhiyong ; Shen, Feng ; Jiang, Jiana

OBJECTIVE:

We aim to compare the clinical efficacy and safety of albumin-bound paclitaxel (nab-PTX) (125 mg/m2, q2w) for two weeks and (125 mg/m2, d1, d8, q3w) for three weeks in the first-line treatment of advanced pancreatic cancer.

METHODS:

The medical records of patients with advanced pancreatic cancer who received nab-PTX for 2 weeks and 3 weeks, combined with gemcitabine, from July 2018 to January 2023, were retrospectively analyzed. The efficacy and adverse reactions of the two groups of patients were compared.

RESULT:

A total of 64 patients were included. The median progression-free survival (mPFS) of the 2-week group was 5.6 months, while the 3-week group was 7.8 months. The median overall survival (mOS) of the 2-week group was 14.0 months, while the 3-week group was 14.7 months. The multivariate analysis showed that a physical fitness status score of 0-1 was an independent factor with better OS, while metastatic sites ≥ 3 were related to poor OS. The incidence of leukopenia or neutropenia, neurotoxicity, fatigue, and poor appetite in the 2-week group was lower than that in the 3-week group.

CONCLUSION:

The clinical efficacy of nab-PTX in the 2-week and dose intensive 3 week did not show significant difference, but the 2-week treatment group had better tolerance and safety.

2026-12-31·Human Vaccines & Immunotherapeutics

Durable response of anaplastic thyroid cancer to pembrolizumab combined with chemotherapy: A case report

Article

作者: Zhuang, Yihan ; Chen, Qiongshan ; Lin, Wen ; Chen, Zipei

Anaplastic thyroid cancer is a notoriously aggressive malignancy with a dismal prognosis, typically associated with a median overall survival of less than one year. Therapeutic alternatives are particularly limited for patients without actionable driver mutations. Here, we report a case of BRAF V600E wild-type, PD-L1-positive (tumor proportion score of 80%) anaplastic thyroid cancer with residual/relapsed disease following surgery and subsequent progression on multi-targeted tyrosine kinase inhibitor therapy. The patient was thereafter treated with a combination of pembrolizumab, nab-paclitaxel and carboplatin, resulting in a sustained near-complete response lasting over 30 months, accompanied by a manageable safety profile. The favorable response in this case suggests that further evaluation of this triplet regimen could be considered for anaplastic thyroid cancer, though this remains a speculative premise requiring validation. Further studies are also needed to clarify the underlying mechanisms of this combination and to identify predictive biomarkers for patient selection.

2026-12-31·DRUG DELIVERY

The colloidal stability of albumin-based drug delivery systems has a profound effect on tumoricidal activity

Article

作者: Jiang, Chengwei ; Schätzlein, Andreas G. ; Uchegbu, Ijeoma F. ; Xiong, Guojun

Human serum albumin (HSA) has attracted significant attention in drug delivery since the approval of Abraxane in 2005. Abraxane is a nanoparticle albumin-bound paclitaxel (nab-PTX) formulation. Although HSA offers advantages such as prolonged circulation time (half-life ~19 days) and intrinsic hydrophobic pockets, the translation of other HSA-based nanomedicines remains limited. In fact, the significant differences between native and pharmaceutical HSA in protein structure and biological interactions could hinder their translational use in drug delivery. In this study, we demonstrate that pharmaceutical HSA (α-helix = 17%) is structurally denatured compared with native HSA (α-helix = 68%), leading to rapid clearance (<1 h) from the circulation and that drug loading is driven by pharmaceutical HSA's amphiphilicity rather than by its hydrophobic pockets. Here, we revealed that Nab-PTX is composed of protein-coated PTX solid cores. These nanosystems have insufficient surface charge (ζ = -13.7 mV), leading to aggregation, and low colloidal stability, resulting in premature drug release upon dilution (<0.1 mg/mL). To address these shortcomings, we developed HSA-polylactic acid (HSA-PLA) nanoparticles with enhanced negative surface charge (ζ = -27.4 mV) and improved colloidal stability to reduce the premature release of encapsulated PTX upon dilution (<0.01 mg/mL). In tumor models, comparative pharmacokinetics, biodistribution, and efficacy studies demonstrated that HSA-PLA (PTX) nanoparticles reduce premature drug release, resulting in greater tumor exposure (129 ± 3 vs. 90 ± 12 µg·h/g, p < 0.01) and superior antitumor efficacy compared with Abraxane. These improvements further suggest that optimization may require only a simple modification when guided by proper theoretical principles.

2,962

项与白蛋白结合型紫杉醇相关的新闻（医药）

2026-05-20

·ioncology

三阴性乳腺癌术前免疫疗效早预测

点击蓝字，关注我们三阴性乳腺癌虽然具有免疫原性，但是仅仅部分患者能对术前免疫检查点抑制剂联合化疗获益。目前缺乏可用于指导医生筛选患者并且根据早期疗效变化动态调整治疗方案的生物学预测指标，而且既往研究大多局限于治疗前单一时间点。 2026年5月19日，欧洲肿瘤内科学会官方期刊《肿瘤学年鉴》在线发表意大利、中国台湾、奥地利、西班牙、美国、德国、俄罗斯、爱尔兰、匈牙利、英国等地学者的NeoTRIP研究报告，通过治疗前后两个时间点的基因转录组分析，探讨了三阴性乳腺癌术前化疗±免疫检查点抑制剂阿替利珠单抗疗效的预测因素。 NeoTRIP / NeoTRIPaPDL1 / NeoTRIP Michelangelo (NCT02620280): Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1 Official Title: Neo-Adjuvant Study With the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer Undergoing Treatment With Nab-paclitaxel and Carboplatin 该国际多中心随机对照三期临床研究于2016年5月至2018年12月入组高风险三阴性乳腺癌患者280例，按1比1随机分为两组： CT组142例：术前卡铂＋白蛋白紫杉醇 CT/A组138例：术前卡铂＋白蛋白紫杉醇＋阿替利珠单抗在治疗前和第二个治疗周期第一天采集肿瘤活检样本，采用纵向基因转录测序分析标志基因、免疫相关基因和铁死亡相关基因的特征，通过单因素逻辑回归和多因素人工智能机器学习模型分析与病理完全缓解的相关性。结果发现，治疗前CT/A组增殖水平较高和基质及代谢程序较低与病理完全缓解率较高相关，治疗早期活检样本没有肿瘤细胞是两组患者手术时病理完全缓解的较强预测因素。治疗期间与治疗前样本的比较表明，肿瘤细胞增殖减少、免疫和基质特征增强。病理完全缓解患者这些变化更为显著，尤其化疗联合免疫治疗患者。免疫反卷积分析证实治疗期间肿瘤微环境动态重塑，表现为免疫细胞群富集和肿瘤上皮细胞比例降低。虽然某些代谢特征在治疗前与预后相关，但是大多数在治疗期间失去预测价值，此时免疫相关程序成为疗效的主要相关因素。探索性多因素分析表明，治疗期间细胞毒性免疫活性和铁代谢对影响化疗免疫疗效发挥互补作用。因此，该研究结果表明，纵向转录组分析揭示三阴性乳腺癌术前治疗期间肿瘤及其微环境的动态重塑，治疗前肿瘤内在特征和早期治疗诱导免疫激活可为预测化疗±阿替利珠单抗疗效提供互补信息，治疗期间活检标本早期肿瘤细胞清除是病理完全缓解的有力替代指标，并支持探索根据疗效的术前治疗策略。该研究的优势：纵向设计和随机对照试验背景支撑。与既往大量停留于治疗前单一时间点的静态研究相比，该研究抓住了动态变化这个牛鼻子。癌症治疗不是静止的，而是在不断变化，既往研究大多只看治疗前的肿瘤特征，但是该研究在治疗前和治疗早期的第二个周期都进行活检，该配对设计能够捕捉到药物和免疫系统在肿瘤内部引发的实时交锋，揭示治疗如何一步步改变肿瘤微环境，这在技术上要求极高，但是生物学意义极其深远。多维度交叉验证，结论更扎实。该研究不仅看基因特征，还引入InstaPrism算法进行免疫细胞评分反卷积分析，并特意进行肿瘤纯度校正，这排除了因为肿瘤细胞死得多、免疫细胞占比自然上升的假象，确凿地证明免疫激活是真正的药效反应，而非简单的细胞比例稀释。该严谨逻辑闭环是转化医学非常推崇的。发现潜在的新玩家：铁死亡与代谢。除了大家熟知的免疫信号，该研究还把目光投向铁死亡和代谢重编程，尤其是在多因素模型里提出细胞毒性免疫活性和铁代谢的共同作用影响免疫治疗效果，这为我们将来寻找新药靶点提供了非常有价值的线索。该研究的局限：贵族化的检测，难以普惠大众。该研究核心是根据全转录组测序，这在大型研究中心做科研没有问题，但是对于广大基层医院而言，成本太高、流程太复杂、出结果太慢。临床医生需要像免疫组织化学染色那样简单、快捷、便宜的预测工具，例如三阴性乳腺癌复旦四分型。如何将几十个基因的特征浓缩成几个核心蛋白质的试剂盒，是下一步必须解决的转化问题。缺乏独立的外部验证集。虽然该研究基于NeoTRIP这样优秀的国际多中心三期试验，但是全部的模型构建和验证都在同一个队列内完成，即使是交叉验证，这在统计学上容易产生过拟合。如果能用完全独立的、比如我们中国的三阴性乳腺癌大队列印证该多基因模型，那该结论的分量将呈指数级上升。依然没有回答停药或换药的终极问题。该研究发现第二个治疗周期第一天没有肿瘤细胞是病理完全缓解的较强预测因素，但是临床医生更需要知道如果第二个治疗周期第一天没有肿瘤细胞，我们能不能提前做手术？或者能不能减免后续治疗？反之，如果第二个治疗周期第一天完全没有免疫激活，我们是否应该立刻更换靶向药或参加其他临床试验？该研究提供了预测，但是没有给出明确的干预阈值。该研究的重大意义：打破了基因检测只看一次的传统观念，向我们证明治疗是动态博弈的过程，尤其加入免疫治疗后，肿瘤微环境的觉醒和重塑比肿瘤本身的初始状态更重要，这彻底改变了我们对生物学指标的认知，将来的趋势一定是动态监测。为免疫＋化疗的协同作用提供了完美注解，从基因层面给出了答案，化疗不仅杀死了快速增殖的肿瘤细胞、抑制了增殖特征，还为免疫系统腾出了空间，而免疫治疗的加入，则在该基础上引发了更强烈的抗肿瘤免疫反应，两者在基因表达上的动态变化完美互补。为复旦四分型等中国原创方案提供了国际视角的印证：三阴性乳腺癌不是一种病，而是四种病（管腔雄激素受体型、免疫调节型、基底样免疫抑制型、间质型）。该研究同样发现，治疗前的高增殖、低代谢特征，以及治疗后的免疫微环境转化，是决定疗效的核心。这与复旦四分型的核心理念按亚型精准打击是不谋而合的。这说明，无论是中国人群的独特规律，还是国际多中心的宏观数据，都在指向同一个真理：只有摸清肿瘤的底牌，并在治疗中看透肿瘤的变化，我们才能真正攻克三阴性乳腺癌。总而言之，该研究是极具启发性的前沿探索，没有停留在过去非黑即白的免疫检查点表达上，而是用发展的眼光，为我们展示了疗效产生的动态生物学机制。对于我们临床医生而言，这不仅是研究报告，更是指引未来开展根据早期疗效动态调整术前治疗的蓝图。我们要做的就是沿着这个方向，继续脚踏实地，把实验室的发现转化为患者手中实实在在的救命药。相关链接从空间预测三阴性乳腺癌免疫疗效一张静态快照预测乳腺癌动态变化自然综述：人类乳腺癌免疫学 Ann Oncol. 2026 May 19. IF: 65.4 Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial. Dugo M, Huang CS, Egle D, Bermejo B, Seitz RS, Nielsen TJ, Zamagni C, Thill M, Antón-Torres A, Russo S, Sevillano E, Ciruelos EM, Schweitzer BL, Galbardi B, Greil R, Semiglazov V, Colleoni M, Kelly CM, Del Mastro L, Mariani G, Viale Gi, Gyorffy B, Ali HR, Pusztai L, Viale G, Callari M, Gianni L, Bianchini G. IRCCS Ospedale San Raffaele, Milan, Italy; Istituto Europeo di Oncologia IRCCS, Milan, Italy; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy; Fondazione Michelangelo, Milan, Italy; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy; IRCCS Ospedale Policlinico San Martino, Genova, Italy; Università di Genova, Genova, Italy; National Taiwan University Hospital, College of Medicine, National Taiwan University and Taiwan Breast Cancer Consortium, Taipei City, Taiwan, China; Medical University Innsbruck, Innsbruck, Austria; Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-CCCIT; and Cancer Cluster Salzburg, Salzburg, Austria; Hospital Clinico Universitario de Valencia, Valencia, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Instituto de Investigación Sanitaria HM Hospitales, Madrid, Spain; University Hospital 12 de Octubre, Madrid, Spain; Insight Molecular Diagnostics Inc. Nashville, TN, USA; Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA; Kliniken Markus-Krankenhaus, Agaplesion, Frankfurt Am Main, Germany; N. N. Petrov Research Institute of Oncology, St. Petersburg, Russian; Mater Private Hospital, Dublin, Ireland; Semmelweis University, H-1094, Budapest, Hungary; University of Pecs, H-7624, Pecs, Hungary; Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, H-1117, Budapest, Hungary; CRUK Cambridge Institute, University of Cambridge, Cambridge, UK; Addenbrookes Hospital, Cambridge, UK. HIGHLIGHTS Baseline proliferation and metabolic signatures predict response to neadjuvant chemotherapy plus atezolizumab in TNBC. Early absence of tumor cells at D1C2 biopsy is a strong surrogate of final pathologic complete response. On-treatment immune activation and reduced proliferation associate with pCR, especially with atezolizumab. Longitudinal transcriptomics reveals treatment-induced microenvironment remodeling linked to response. Multi-signature models improve prediction and identify distinct baseline and on-treatment predictors by arm. BACKGROUND: Triple-negative breast cancer (TNBC) is immunogenic, but only a subset of patients benefits from neoadjuvant immune checkpoint inhibitors (ICIs) combined with chemotherapy. Predictive biomarkers to guide patient selection and treatment adaptation are lacking. PATIENTS AND METHODS: In the randomized phase III NeoTRIPaPDL1 trial, 280 patients with high-risk TNBC received neoadjuvant carboplatin plus nab-paclitaxel (CT, n=142) or the same regimen with atezolizumab (CT/A, n=138). Tumor biopsies were collected at baseline and on the first day of the second cycle (D1C2). Longitudinal RNA sequencing was performed to evaluate hallmark, immune, and ferroptosis-related gene signatures. Associations with pathologic complete response (pCR) were assessed using univariable logistic regression and multivariable XGBoost models. RESULTS: At baseline, in the CT/A arm higher proliferation and lower stromal and metabolic programs were associated with increased pCR rate. Absence of tumor cells in early on-treatment biopsies strongly predicted surgical pCR in both treatment arms. Comparison of on-treatment with baseline samples revealed a reduced proliferation and increased immune and stromal signatures. These changes were more pronounced in tumors achieving pCR, particularly in patients receiving chemoimmunotherapy. Immune deconvolution analyses confirmed dynamic remodeling of the tumor microenvironment during treatment, with response-associated enrichment of immune cell populations and reduction of tumor epithelial fractions. While several metabolic signatures were associated with outcome at baseline, most lost predictive value on-treatment, where immune-related programs became the dominant correlates of response. Exploratory multivariable analyses suggested complementary contributions of on-treatment cytotoxic immune activity and iron metabolism in shaping response to chemoimmunotherapy. CONCLUSIONS: Longitudinal transcriptomic profiling revealed dynamic tumor and microenvironment remodeling during neoadjuvant therapy in TNBC. Baseline tumor-intrinsic features and early treatment-induced immune activation provide complementary information for predicting response to chemoimmunotherapy. Early tumor clearance in on-treatment biopsies represents a strong surrogate of pCR and supports investigation of response-adapted neoadjuvant strategies. KEYWORDS: Triple-negative breast cancer, neoadjuvant therapy, immunotherapy, longitudinal sampling, transcriptomic profiling, predictive biomarker DOI: 10.1016/j.annonc.2026.05.694 （来源：SIBCS）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

2026-05-20

·ioncology

指南优解丨刘德林教授解读2026CSCO胃癌指南更新：HER2阳性胃癌二线治疗正式迈入抗HER2靶向时代

点击蓝字，关注我们编者按：胃癌是全球范围内常见的恶性肿瘤，其诊疗策略的不断演进深刻影响着患者的生存预后与生活质量。近年来，随着精准医学理念的深入与创新药物的涌现，胃癌治疗格局正经历着前所未有的变革。近期，《中国临床肿瘤学会（CSCO）胃癌诊疗指南（2026）》发布，系统性地整合了过去一年中的突破性循证医学证据与临床实践进展，为胃癌的规范化、精准化诊疗提供了权威指引。本次指南更新的一大核心亮点，在于彻底重塑了HER2阳性晚期胃癌的治疗路径，尤其是二线治疗策略的革新，标志着该领域正式迈入了以抗HER2靶向治疗为中心的全程管理新时代。《肿瘤瞭望》特邀江苏省肿瘤医院刘德林教授深度剖析本次指南更新的关键变化、核心依据及临床指导意义。二线治疗策略的历史性革新本次指南修订紧密贴合中国临床实践，深刻体现了“精准治疗”理念已全面覆盖胃癌诊疗的全流程。在晚期胃癌的治疗版图中，分子分型的价值被提升至前所未有的高度。新版指南明确将HER2、错配修复（MMR）、程序性死亡配体1（PD-L1，采用联合阳性评分CPS）以及Claudin18.2四个关键生物标志物作为I级推荐检测靶点。这种多维度、整合性的精准诊疗思维，旨在为每一位患者寻找到最匹配的治疗策略。在HER2阳性胃癌的全程治疗布局中，二线治疗长期以来是临床实践中的难点与瓶颈。既往，患者在一线治疗进展后，往往缺乏抗HER2靶向治疗方案，多以传统化疗或抗血管生成药物为主，疗效有限且生存获益亟待提升。十余年来，胃癌二线抗HER2治疗难有寸进，多项试图确立二线靶向治疗地位的临床研究均以失败告终。其中，Tytan研究[1]探索了酪氨酸激酶抑制剂（TKI）拉帕替尼的应用，GATSBY研究[2]评估了ADC药物恩美曲妥珠单抗（T-DM1）的疗效，T-ACT研究[3]则尝试了曲妥珠单抗的跨线治疗策略，但这些研究均未能较化疗改善患者的总生存期（OS）。这些探索的接连失利，使得临床医生在面对一线治疗进展后的患者时，长期缺乏有效的抗HER2靶向治疗手段，这也凸显了该领域未被满足的巨大临床需求。随着靶向HER2抗体偶联药物（ADC）相关临床研究的成功，这一局面被彻底改写。基于关键的DESTINY-Gastric04研究[4]提供的坚实证据，德曲妥珠单抗（T-DXd）获得了国家药品监督管理局（NMPA）的批准[5]，用于HER2阳性晚期胃癌的二线治疗。正是基于这一里程碑式的突破，2026版《CSCO胃癌指南》[6]做出了历史性的修订：将T-DXd单药治疗新增为HER2阳性胃癌二线治疗的唯一I级推荐方案，并赋予其1A类证据等级。 2026版《CSCO胃癌指南》新增T-DXd单药治疗为HER2阳性胃癌二线治疗的唯一I级推荐方案，并赋予其1A类证据等级 DESTINY-Gastric04研究的结果清晰地展示了T-DXd在HER2阳性胃癌二线治疗中的疗效。该研究头对头比较了T-DXd与当时标准治疗方案（雷莫西尤单抗联合紫杉醇）的疗效与安全性。数据显示，T-DXd治疗组在关键疗效终点上均取得了显著优势：客观缓解率（ORR）达到44.3%，显著优于对照组的29.1%；中位无进展生存期（mPFS）延长至6.7个月，对照组则为5.6个月；更重要的是，中位总生存期（mOS）获得了具有临床意义的延长，T-DXd组为14.7个月，而对照组为11.4个月。这些数据表明，T-DXd不仅能够为更多患者带来肿瘤的显著缩小，更能有效延缓疾病进展，并最终转化为生存期的显著延长，为二线治疗树立了新的疗效标杆。 DESTINY-Gastric04研究设计 DESTINY-Gastric04研究OS结果除了卓越的疗效，治疗的安全性与耐受性同样是临床决策中的关键因素。T-DXd单药治疗在取得更优疗效的同时，其不良反应整体上处于可控范围。T-DXd作为一种靶向性更强的ADC药物，能够在一定程度上减少患者对传统细胞毒性化疗的依赖与恐惧，为患者提供了疗效与生活质量更优平衡的治疗选择。构建全程抗HER2治疗新格局 T-DXd在二线治疗中的确立，其意义远不止于填补了一个治疗阶段的空白，它更深远的影响在于串联并激活了HER2阳性胃癌的“全程抗HER2治疗”链条。新版指南的更新，标志着晚期HER2阳性胃癌正式进入了“全程抗HER2时代”。这意味着，从一线到二线，乃至三线及其后，抗HER2治疗成为了贯穿疾病管理始终的核心策略。在一线治疗阶段，治疗已进入“靶免联合”时代，在确认HER2阳性的基础上，通过PD-L1等检测进一步指导是否联合免疫检查点抑制剂，形成了多药联合的强化治疗方案。当一线治疗进展后，患者无需中断抗HER2治疗，可直接转换至以T-DXd为代表的二线抗HER2靶向方案，持续抑制HER2信号通路。纵观2026版《CSCO胃癌指南》的更新，中国在胃癌领域的创新药物研发、主导的全球多中心临床研究以及基于本土实践形成的指南共识，正日益受到国际学术界的广泛关注与认可。众多中国原研的创新药物，无论是否已纳入本次指南，其首创性已得到国际同行承认。中国的研究者们在全球胃癌临床研究中扮演着越来越重要的领导者角色，不断推动着中国胃癌诊疗水平迈向国际前沿。小结 2026版《CSCO胃癌指南》的发布是胃癌精准治疗道路上的又一重要里程碑。其中，HER2阳性胃癌二线治疗策略的革新——T-DXd作为唯一I级推荐方案[1A类证据]的确立，具有划时代的意义。它不仅仅是一个新药物的推荐，更代表了一种治疗范式的根本转变：从二线治疗缺乏有效靶向手段，到正式迈入以抗HER2靶向治疗为核心的全程管理时代。这一转变根植于坚实的临床研究证据，着眼于患者生存获益的最大化，并依托于指南的规范化推广而落地实践。随着全程抗HER2治疗格局的构建，以及Claudin18.2、PD-L1等其他靶点精准治疗的同步成熟，胃癌的诊疗正朝着分子分型指导下的、高度个体化的方向加速前进。未来，随着更多创新研究的开展与临床实践的深化，中国胃癌诊疗水平必将持续提升，为全球抗癌事业贡献更多的中国力量与中国智慧。 ▌参考文献： [1] Satoh T, Xu RH, Chung HC, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. J Clin Oncol. 2014;32(19):2039-2049. doi:10.1200/JCO.2013.53.6136 [2] Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18(5):640-653. doi:10.1016/S1470-2045(17)30111-0 [3] Makiyama A, Sukawa Y, Kashiwada T, et al. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study). J Clin Oncol. 2020;38(17):1919-1927. doi:10.1200/JCO.19.03077 [4] Shitara K, et al. Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study. 2025 ASCO.LBA4002 [5] 国家药品监督管理局. 2026年01月22日药品批准证明文件送达信息. (2026-01-22). https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20260122171453170.html. [6]中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会（CSCO）胃癌诊疗指南2026. 刘德林教授江苏省肿瘤医院内科主任医师肿瘤学博士硕士研究生导师中国抗癌协会多原发和不明原发肿瘤整合康复专业委员会常委中国老年保健协会诊疗技术创新与消化康复分会副秘书长中国文化促进会医院医师分会副会长江苏省肿瘤专业质控中心副主任委员中国老年学和老年医学学会精准医疗分会委员北京癌症防治学会食管癌专委会委员江苏省老年医学学会肿瘤学分会常委江苏省肿瘤专业质控中心食管癌质控专家委员会委员兼内科组秘书江苏省肿瘤防治联盟食管癌专家委员会常委江苏省整合医学研究会第一届运动能量疗愈专委会委员江苏省第一届肿瘤化疗与生物治疗神经内分泌学组副组长江苏省抗癌协会第一届胃癌专业委员会青年委员江苏省肿瘤防治联盟肠癌专家委员会委员江苏省老年学学会慢性病专业委员会委员人民网、人民健康2020年度“人民好医生▪金山茶花▪优秀典范”称号，参编《肿瘤内科临床医嘱手册》、《肿瘤学基础与治疗总论》、《临床常见肿瘤综合治疗》、《临床罕见肿瘤学》，《多原发与不明原发肿瘤》等肿瘤学教材及专著，专家共识；主持省自然基金/ CSCO基金/白求恩基金各一项，参与国家、省厅级及CSCO基金多项。（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

CSCO会议抗体药物偶联物

2026-05-20

·肿瘤界

2026 ASCO | 胃食管肝胆胰肿瘤中国研究一览

点击蓝字关注我们 // 2026年美国临床肿瘤学会（ASCO）年会将于当地时间5月29日至6月2日在美国芝加哥盛大召开。ASCO年会作为全球肿瘤学领域的顶级盛会，汇聚了来自世界各地的肿瘤学专家、医生和研究人员，旨在分享最新的研究成果、探讨最前沿的诊疗技术，推动肿瘤学领域的不断进步。本文特别整理了胃食管肝胆胰肿瘤领域的中国研究，邀您先睹为快！胃食管癌摘要号：2511 研究名称（英文）：Personalized neoantigen vaccine as adjuvant therapy in high-risk postoperative esophageal carcinoma 研究名称（中文）：个性化新抗原疫苗用于高危术后食管癌的辅助治疗讲者：吴明 | 浙江大学医学院附属第二医院报告类型：Clinical Science Symposium 摘要号：2513 研究名称（英文）：Perioperative tislelizumab plus chemotherapy versus chemotherapy in MHC-II positive/MHC-II negative locally advanced GC/GEJC: A prospective, randomized, open-label, biomarker-driven, phase 2 trial 研究名称（中文）：围手术期替雷利珠单抗联合化疗对比单纯化疗治疗 MHC-II 阳性/MHC-II 阴性局部晚期胃癌/胃食管结合部癌：一项前瞻性、随机、开放标签、生物标志物驱动的Ⅱ期临床试验讲者：程向东 | 浙江省肿瘤医院报告类型：Rapid Oral Abstract Session 摘要号：4003 研究名称（英文）：First-line treatment of QLS31905 plus chemotherapy in patients with pancreatic cancer and gastric cancer: Data from a phase 1b/2 study 研究名称（中文）：QLS31905联合化疗一线治疗胰腺癌和胃癌患者：来自1b/2期研究的数据讲者：张小田 | 北京大学肿瘤医院报告类型：Oral Abstract Session 摘要号：4008 研究名称（英文）：Izalontamab brengitecan (iza-bren) versus chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, open-label, phase III study. 研究名称（中文）：Izalontamab brengitecan（iza-bren）对比化疗用于复发或转移性食管鳞状细胞癌（ESCC）患者：一项多中心、随机、开放标签的III期研究讲者：鲁智豪 | 北京大学肿瘤医院报告类型：Oral Abstract Session 摘要号：4009 研究名称（英文）：Neoadjuvant/adjuvant serplulimab vs. placebo combined with chemotherapy for PD-L1–positive gastric cancer: A randomized, double-blind, multicenter phase 3 study. 研究名称（中文）：斯鲁利单抗联合化疗对比安慰剂联合化疗用于PD-L1阳性胃癌的新辅助/辅助治疗：一项随机、双盲、多中心III期研究讲者：沈琳 | 北京大学肿瘤医院报告类型：Rapid Oral Abstract Session 摘要号：4011 研究名称（英文）：A phase 2 pivotal study of savolitinib in patients with MET-amplified gastric cancer or gastroesophageal junction adenocarcinomas 研究名称（中文）：赛沃替尼治疗MET扩增胃癌或胃食管结合部腺癌的II期关键性研究讲者：彭智 | 北京大学肿瘤医院报告类型：Rapid Oral Abstract Session 摘要号：LBA4026 研究名称（英文）：Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (Chemo)/trastuzumab (Tra) for first-line (1L) HER2-expressing locally advanced or metastatic (la/m) gastric cancer (GC): Updated results from the RC48-C027 trial 研究名称（中文）：维迪西妥单抗（DV）联合特瑞普利单抗（Tor）及化疗/曲妥珠单抗一线治疗HER2表达局部晚期或转移性胃癌：RC48-C027试验更新结果讲者：彭智 | 北京大学肿瘤医院报告类型：Poster 摘要号：4027 研究名称（英文）：A phase 2 clinical study of nimotuzumab plus S-1 and concurrent radiotherapy in 75 years and older patients with esophageal squamous cell carcinoma 研究名称（中文）：尼妥珠单抗联合S-1及同步放疗治疗75岁及以上食管鳞状细胞癌患者的II期临床研究讲者：Xiaojie Xia | 南京医科大学第一附属医院报告类型：Poster 摘要号：4045 研究名称（英文）：Efficacy and safety of tecotabart vedotin plus toripalimab with or without chemotherapy as first-line treatment for CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma: Phase II study results 研究名称（中文）：Tecotabart vedotin联合特瑞普利单抗±化疗一线治疗CLDN18.2阳性晚期胃或胃食管结合部腺癌的疗效与安全性：II期研究结果讲者：李进 | 中国药科大学上海高博肿瘤医院报告类型：Poster 摘要号：4054 研究名称（英文）：Update results of benmelstobart plus anlotinib combined with SOX in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with low PD-L1 expression: A single-arm, multicenter phase II clinical trial 研究名称（中文）：Benmelstobart联合安罗替尼及SOX方案一线治疗低PD-L1表达晚期胃或胃食管结合部（G/GEJ）腺癌的更新结果：一项单臂、多中心II期临床试验讲者：Yong-Xu Jia | 郑州大学第一附属医院报告类型：Poster 摘要号：4056 研究名称（英文）：Heterogeneity in biomarkers for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC) across regions: Insights from CheckMate-649 研究名称（中文）：CheckMate-649研究中晚期胃癌、胃食管结合部癌及食管腺癌（GC/GEJC/EAC）生物标志物的区域异质性分析讲者：沈琳 | 北京大学肿瘤医院报告类型：Poster 摘要号：4057 研究名称（英文）：Sintilimab combined with short-course intensified chemotherapy regimen nab-POF in the treatment of metastatic gastric cancer (FDZL-GC002): A single-arm, phase 2 trial 研究名称（中文）：信迪利单抗联合短程强化化疗方案nab-POF治疗转移性胃癌（FDZL-GC002）：一项单臂II期试验讲者：Weijian Guo | 复旦大学附属肿瘤医院报告类型：Poster 摘要号：4059 研究名称（英文）：Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (ImpactCRT): Long-term outcomes of a single-arm phase II trial 研究名称（中文）：诱导化疗联合卡瑞利珠单抗序贯同步放化疗治疗不可切除局部晚期食管鳞状细胞癌（ImpactCRT研究）：一项单臂II期试验的长期结局讲者：Fang Peng | 中山大学附属第一医院报告类型：Poster 摘要号：4063 研究名称（英文）：Biomarker-driven assessment of immunochemotherapy with or without fruquintinib as first-line treatment for advanced gastric/GEJ adenocarcinoma: Initial clinical results and subgroup analysis from the MGC-FLORA study 研究名称（中文）：生物标志物驱动的免疫化疗±呋喹替尼一线治疗晚期胃/胃食管交界处腺癌：MGC-FLORA研究的初步临床结果及亚组分析讲者：xiaodong zhu | 复旦大学附属肿瘤医院报告类型：Poster 摘要号：4065 研究名称（英文）：Disitamab vedotin (RC48), tislelizumab, and S-1 as first-line therapy for HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Updated survival and exploratory biomarker results from the RCTS trial 研究名称（中文）：维迪西妥单抗、替雷利珠单抗联合替吉奥一线治疗HER2过表达晚期胃/胃食管交界处腺癌：RCTS试验的更新生存及探索性生物标志物结果讲者：刘联 | 山东大学齐鲁医院报告类型：Poster 摘要号：4067 研究名称（英文）：Efficacy of nimotuzumab combined with concurrent chemoradiotherapy for patients with postoperative loco‑regional recurrent esophageal squamous cell carcinoma: A phase II study 研究名称（中文）：尼妥珠单抗联合同步放化疗治疗术后局部区域复发性食管鳞癌的疗效：一项II期研究讲者：Jialiang Zhou | 江南大学附属医院报告类型：Poster 摘要号：4071 研究名称（英文）：Non-invasive strategy for gastric cancer detection: Integration of cell-free DNA fragmentomics and protein biomarkers 研究名称（中文）：无创胃癌检测策略：整合游离DNA片段组学和蛋白生物标志物讲者：Lian Lian | 苏州市相城人民医院报告类型：Poster 摘要号：4077 研究名称（英文）：FGF4-mediated resistance to combined anti-angiogenic and immunotherapy in esophageal squamous cell carcinoma via suppression of high endothelial venules and tertiary lymphoid structure formation 研究名称（中文）：FGF4通过抑制高内皮微静脉及三级淋巴结构形成介导食管鳞癌抗血管生成联合免疫治疗的耐药性讲者：Weixiong Yang | 中山大学附属第一医院报告类型：Poster 摘要号：4079 研究名称（英文）：Total neoadjuvant immunotherapy plus chemotherapy in Borrmann type IV gastric cancer (PERISCOPE-01 study): An open-label, single-arm, phase 2 trial 研究名称（中文）：Borrman IV型胃癌的全新辅助免疫联合化疗（PERISCOPE-01研究）：开放标签、单臂、II期试验讲者：邱海波 | 中山大学肿瘤防治中心报告类型：Poster 摘要号：LBA4082 研究名称（英文）：Pathological complete response and ctDNA analyses in SCIENCE: Results from a randomized, phase III trial of neoadjuvant chemotherapy plus sintilimab and chemoradiotherapy plus sintilimab versus chemoradiotherapy in resectable locally advanced esophageal squamous cell carcinoma 研究名称（中文）：SCIENCE研究的病理完全缓解及ctDNA分析：新辅助化疗+信迪利单抗 vs 放化疗+信迪利单抗 vs 单纯放化疗治疗可切除局部晚期食管鳞癌的随机III期试验结果讲者：冷雪峰 | 四川省肿瘤医院报告类型：Poster 摘要号：4084 研究名称（英文）：Paclitaxel/cisplatin (TP) vs cisplatin/5-fluorouracil (PF) neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma (ESCC): A randomized trial 研究名称（中文）：紫杉醇+顺铂对比顺铂+5-氟尿嘧啶新辅助放化疗治疗局部晚期食管鳞癌的随机试验讲者：Chien-Huai Chuang | 台湾大学癌症中心报告类型：Poster 摘要号：4085 研究名称（英文）：Phase II study of adjuvant nab-paclitaxel plus S-1 after D2 resection in stage III diffuse gastric cancer (NORDICA study) 研究名称（中文）：D2切除术后III期弥漫型胃癌辅助白蛋白结合型紫杉醇联合替吉奥的II期研究（NORDICA研究）讲者：Ke Peng | 复旦大学附属中山医院报告类型：Poster 摘要号：4087 研究名称（英文）：Perioperative therapy with tifcemailmab plus toripalimab and chemotherapy for resectable thoracic esophageal squamous cell carcinoma (BT-NICE trial): A prospective phase II study 研究名称（中文）：Tifcemailmab联合特瑞普利单抗及化疗围术期治疗可切除胸段食管鳞癌（BT-NICE试验）：前瞻性II期研究讲者：chengzhi ding | 河南省人民医院报告类型：Poster 摘要号：4089 研究名称（英文）：Neoadjuvant cadonilimab plus CapeOX in patients with clinical stage III gastric or esophagogastric junction adenocarcinoma (GC/EGJC): A prospective, single-arm phase II study 研究名称（中文）：卡度尼利单抗联合CapeOX新辅助治疗临床III期胃或食管胃交界处腺癌：前瞻性、单臂II期研究讲者：Liying Zhao | 南方医科大学南方医院报告类型：Poster 摘要号：4090 研究名称（英文）：Neoadjuvant adebrelimab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: A single-arm, phase II trial 研究名称（中文）：阿得贝利单抗联合化疗新辅助治疗局部晚期食管鳞癌：单臂II期试验讲者：Chao Wu | 中国人民解放军总医院报告类型：Poster 摘要号：4091 研究名称（英文）：Neoadjuvant tislelizumab plus oxaliplatin and S-1 for locally advanced Siewert type II esophagogastric junction adenocarcinoma: A prospective multicenter phase II study 研究名称（中文）：替雷利珠单抗联合奥沙利铂及替吉奥新辅助治疗局部晚期Siewert II型食管胃交界处腺癌：前瞻性多中心II期研究讲者：Yanzhao Xu | 河北医科大学第四医院报告类型：Poster 摘要号：4092 研究名称（英文）：SCALE-2: A phase 2 trial evaluating neoadjuvant short-course radiotherapy combined with chemotherapy and toripalimab in resectable locally advanced esophageal squamous cell carcinoma 研究名称（中文）：SCALE-2：短程放疗联合化疗及特瑞普利单抗新辅助治疗可切除局部晚期食管鳞癌的II期试验讲者：Ning Jiang | 江苏省肿瘤医院报告类型：Poster 摘要号：4100 研究名称（英文）：Neoadjuvant cadonilimab plus chemotherapy for locally advanced gastric/gastroesophageal junction cancer: A single-arm, phase II trial 研究名称（中文）：卡度尼利单抗联合化疗新辅助治疗局部晚期胃/胃食管交界处癌：单臂II期试验讲者：Pengfei Zhang | 四川大学华西医院报告类型：Poster 摘要号：4102 研究名称（英文）：Perioperative cadonilimab (AK104) in locally advanced MSI-H/dMMR gastric or gastroesophageal junction adenocarcinoma and colorectal adenocarcinoma: A basket study 研究名称（中文）：卡度尼利单抗围术期治疗局部晚期MSI-H/dMMR胃/胃食管交界处腺癌及结直肠腺癌：一项篮式研究讲者：季加孚 | 北京大学肿瘤医院报告类型：Poster 摘要号：4103 研究名称（英文）：Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: A prospective clinical trial 研究名称（中文）：新辅助免疫化疗联合胸腺法新治疗局部晚期胃癌：一项前瞻性临床试验讲者：Hongda Liu | 南京医科大学第一附属医院报告类型：Poster 摘要号：TPS4240 研究名称（英文）：HIPEC combined with NIPS and tislelizumab for conversion therapy in gastric cancer with peritoneal metastasis (P0CY1 or PCI ≤10): A prospective, single-arm, phase II study 研究名称（中文）：HIPEC联合NIPS及替雷利珠单抗转化治疗胃癌伴腹膜转移（P0CY1或PCI ≤10）：前瞻性、单臂II期研究讲者：Honghai Guo | 河北医科大学第四医院报告类型：Poster 摘要号：TPS4245 研究名称（英文）：Efficacy and safety of disitamab vedotin (DV) combined with trastuzumab, and tislelizumab versus chemotherapy (CAPOX) combined with trastuzumab ± pembrolizumab for patients with first-line HER2-high advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA): A randomized controlled phase 3 trial 研究名称（中文）：维迪西妥单抗联合曲妥珠单抗及替雷利珠单抗对比化疗（CAPOX）联合曲妥珠单抗±帕博利珠单抗一线治疗HER2高表达晚期胃/胃食管交界处腺癌的随机对照III期试验讲者：彭智 | 北京大学肿瘤医院报告类型：Poster 摘要号：TPS4248 研究名称（英文）：Chemoradiotherapy plus sintilimab versus chemoradiotherapy as neoadjuvant treatment in locally advanced esophageal squamous cell carcinoma (NEOCRTEC2101): A multicenter, randomized, phase III trial 研究名称（中文）：放化疗联合信迪利单抗对比单纯放化疗新辅助治疗局部晚期食管鳞癌（NEOCRTEC2101）：多中心、随机、III期试验讲者：习勉 | 中山大学肿瘤防治中心报告类型：Poster 肝癌摘要号：2508 研究名称（英文）：Objective response rates with Ori-C101, an armored GPC3-directed CAR-T, in heavily pretreated advanced HCC: Updated results from the phase Ib BEACON study. 研究名称（中文）：靶向GPC3的CAR-T细胞治疗药物 Ori-C101 治疗经多线治疗的晚期肝细胞癌的客观缓解率：Ⅰb期 BEACON 研究更新结果讲者：樊嘉 | 复旦大学附属中山医院报告类型：Oral Abstract Session 摘要号：4001 研究名称（英文）：Camrelizumab (C) plus rivoceranib (R) with transarterial chemoembolization (TACE) vs TACE alone in unresectable hepatocellular carcinoma (uHCC): A randomized, phase 3 trial. 研究名称（中文）：卡瑞利珠单抗联合阿帕替尼联合经动脉化疗栓塞（TACE）对比单纯TACE治疗不可切除肝细胞癌的随机III期试验讲者：荚卫东 | 中国科学技术大学附属第一医院报告类型：Oral Abstract Session 摘要号：4014 研究名称（英文）：Nilvanstomig (ZG005), an anti-PD-1/TIGIT bispecific antibody, plus bevacizumab vs. sintilimab plus bevacizumab biosimilar as first-line therapy for advanced hepatocellular carcinoma: A randomized, multi-center, phase II trial. 研究名称（中文）：Nilvanstomig（ZG005），一种抗PD-1/TIGIT双特异性抗体，联合贝伐珠单抗对比信迪利单抗联合贝伐珠单抗生物类似物一线治疗晚期肝细胞癌的随机、多中心II期试验讲者：吴泓 | 四川大学华西医院报告类型：Rapid Oral Abstract Session 摘要号：待定研究名称（英文）：Finding the Right Time and Place for Immunotherapy in Hepatocellular Carcinoma 研究名称（中文）：寻找肝细胞癌免疫治疗的最佳时机与场景讲者：陈林 | 香港中文大学报告类型：Oral Abstract Session 摘要号：4107 研究名称（英文）：Efficacy and safety of transarterial chemoembolization combined with donafenib for hepatocellular carcinoma with rupture and bleeding: A retrospective, cohort study. 研究名称（中文）：经动脉化疗栓塞联合多纳非尼治疗伴破裂出血的肝细胞癌的疗效与安全性：回顾性队列研究讲者：Qi Zhang | 十堰市人民医院报告类型：Poster 摘要号：4113 研究名称（英文）：Neoadjuvant radiotherapy combined with lenvatinib and sintilimab in patients with resectable hepatocellular carcinoma with portal vein tumor thrombus: An open-label, single-arm, multicenter, prospective phase I clinical trial. 研究名称（中文）：新辅助放疗联合仑伐替尼及信迪利单抗治疗可切除伴门静脉癌栓的肝细胞癌：开放标签、单臂、多中心、前瞻性I期临床试验讲者：Bin Shu | 清华大学北京清华长庚医院报告类型：Poster 摘要号：4119 研究名称（英文）：Impact of HSPA6 on lenvatinib resistance in HCC via phase separation–mediated TXNRD1 stabilization and ferroptosis suppression. 研究名称（中文）：HSPA6通过相分离介导的TXNRD1稳定及铁死亡抑制影响仑伐替尼在肝细胞癌中的耐药性讲者：Yi Niu | 中山大学肿瘤防治中心报告类型：Poster 摘要号：4121 研究名称（英文）：Three-month versus six-month duration of postoperative adjuvant therapy after R0 resection following conversion therapy in hepatocellular carcinoma patients achieving MPR or pCR: A prospective randomized study. 研究名称（中文）：肝细胞癌转化治疗后R0切除患者术后辅助治疗3个月对比6个月：在达到MPR或pCR患者中的前瞻性随机研究讲者：Jia-Yi Wu | 福州大学附属省立医院报告类型：Poster 摘要号：4123 研究名称（英文）：A phase II study of bTAE-HAIC combined with lenvatinib and camrelizumab for patients with high tumor burden hepatocellular carcinoma: The TALEM-H trial. 研究名称（中文）：bTAE-HAIC联合仑伐替尼及卡瑞利珠单抗治疗高肿瘤负荷肝细胞癌的II期研究（TALEM-H试验）讲者：Xue Han | 中山大学肿瘤防治中心报告类型：Poster 摘要号：4131 研究名称（英文）：Sequential bTAE-HAIC combined with lenvatinib and sintilimab for infiltrative hepatocellular carcinoma: A single-center perspective. 研究名称（中文）：序贯bTAE-HAIC联合仑伐替尼及信迪利单抗治疗浸润性肝细胞癌：单中心经验讲者：Qunfang Zhou | 中山大学肿瘤防治中心报告类型：Poster 摘要号：4132 研究名称（英文）：Hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitors as first-line treatment for hepatocellular carcinoma with high tumor burden and portal vein tumor thrombus: A target trial emulation study (CHANCE 2416). 研究名称（中文）：肝动脉灌注化疗联合仑伐替尼及PD-1抑制剂一线治疗高肿瘤负荷伴门静脉癌栓的肝细胞癌：目标试验模拟研究（CHANCE 2416）讲者：Jiaxi Liu | 中国医科大学附属第一医院报告类型：Poster 摘要号：4144 研究名称（英文）：Yttrium-90 SIRT plus atezolizumab/bevacizumab in unresectable huge HCC (>10 cm): A multicenter retrospective study. 研究名称（中文）：钇-90选择性内放射治疗联合阿替利珠单抗/贝伐珠单抗治疗不可切除巨大肝细胞癌（>10 cm）：多中心回顾性研究讲者：Hui Zhang | 陆军军医大学第一附属医院报告类型：Poster 摘要号：4148 研究名称（英文）：Effectiveness and safety of IBI310 combined with sintilimab versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma (aHCC): A randomized, open-label, controlled, multicenter phase III clinical study. 研究名称（中文）：IBI310联合信迪利单抗对比索拉非尼一线治疗晚期肝细胞癌的有效性与安全性：随机、开放标签、对照、多中心III期临床研究讲者：樊嘉 | 复旦大学附属中山医院报告类型：Poster 摘要号：4149 研究名称（英文）：Yttrium-90 SIRT followed by lenvatinib plus sintilimab for unresectable intermediate-to-advanced hepatocellular carcinoma: Phase II SIRLENS-90 trial. 研究名称（中文）：钇-90选择性内放射治疗后序贯仑伐替尼联合信迪利单抗治疗不可切除中晚期肝细胞癌：SIRLENS-90 II期试验讲者：Jingjun Huang | 广州医科大学附属第二医院报告类型：Poster 摘要号：4162 研究名称（英文）：An immune-related pathologic response score as a predictor of survival after immune checkpoint inhibitor–based conversion therapy in hepatocellular carcinoma. 研究名称（中文）：免疫相关病理缓解评分作为基于免疫检查点抑制剂转化治疗后肝细胞癌生存的预测因素讲者：Yi-Jun Lu | 复旦大学附属中山医院报告类型：Poster 摘要号：TPS4254 研究名称（英文）：Adjuvant sintilimab plus bevacizumab following curative resection of spontaneously ruptured hepatocellular carcinoma: A prospective exploratory phase II study (CLEAR-2). 研究名称（中文）：自发性破裂肝细胞癌根治性切除后辅助信迪利单抗联合贝伐珠单抗：前瞻性探索性II期研究（CLEAR-2）讲者：Yongjun Chen | 上海交通大学医学院附属瑞金医院报告类型：Poster 摘要号：TPS4257 研究名称（英文）：CAREFOL: A phase 3, randomized, open-label, multicenter trial of camrelizumab and rivoceranib with or without intravenous FOLFOX chemotherapy as first-line treatment for unresectable hepatocellular carcinoma. 研究名称（中文）：CAREFOL：卡瑞利珠单抗联合阿帕替尼±静脉FOLFOX化疗一线治疗不可切除肝细胞癌的III期随机、开放标签、多中心试验讲者：Linhui Peng | 中山大学孙逸仙纪念医院报告类型：Poster 胆道系统肿瘤摘要号：4105 研究名称（英文）：First-line rilvegostomig (R) + chemotherapy (CTx) in advanced biliary tract cancer (BTC): Updated analysis of GEMINI-Hepatobiliary substudy 2 cohort A. 研究名称（中文）：Rilvegostomig联合化疗一线治疗晚期胆道癌：GEMINI-Hepatobiliary子研究2队列A的更新分析讲者：周俭 | 复旦大学附属中山医院报告类型：Poster 摘要号：4110 研究名称（英文）：Tislelizumab combined with donafenib and GEMOX as first-line treatment for advanced biliary tract cancer: A single-arm, phase II study. 研究名称（中文）：替雷利珠单抗联合多纳非尼及GEMOX一线治疗晚期胆道癌：单臂II期研究讲者：Yiming Zhao | 复旦大学附属肿瘤医院报告类型：Poster 摘要号：4112 研究名称（英文）：Bortezomib plus gemcitabine-cisplatin versus gemcitabine-cisplatin as first-line treatment for advanced biliary tract cancers: A randomized phase II clinical trial with exploratory analysis of PTEN status. 研究名称（中文）：硼替佐米联合吉西他滨-顺铂对比吉西他滨-顺铂一线治疗晚期胆道癌：探索PTEN状态的随机II期临床试验讲者：Hui Wang | 海军军医大学第三附属医院报告类型：Poster 摘要号：4116 研究名称（英文）：Association of asynchronous, time-flexible digital multidisciplinary care with overall survival in advanced biliary tract cancer treated with immune checkpoint inhibitors. 研究名称（中文）：异步、时间灵活的数字多学科诊疗与接受免疫检查点抑制剂治疗的晚期胆道癌总生存期的关联讲者：Binhe Tian | 北京协和医院报告类型：Poster 摘要号：4120 研究名称（英文）：NALIRIFOX in combination with adebrelimab for advanced biliary tract cancer: A phase 2 NIOFA-01 clinical trial. 研究名称（中文）：NALIRIFOX联合阿得贝利单抗治疗晚期胆道癌：NIOFA-01 II期临床试验讲者：Qing Zhu | 四川大学华西医院报告类型：Poster 摘要号：4125 研究名称（英文）：First-line tislelizumab plus chemoradiotherapy for patients with advanced biliary tract cancer: A prospective, biomolecular exploratory, phase II trial. 研究名称（中文）：替雷利珠单抗联合放化疗一线治疗晚期胆道癌：前瞻性、生物分子探索性II期试验讲者：Mingzhen Zhou | 南京鼓楼医院报告类型：Poster 摘要号：4127 研究名称（英文）：Distribution and density of tertiary lymphoid structures as predictors of clinical outcomes and immunotherapy responses in gallbladder cancer. 研究名称（中文）：三级淋巴结构的分布和密度作为胆囊癌临床结局及免疫治疗反应的预测因素讲者：Rui Zhang | 西安交通大学第一附属医院报告类型：Poster 摘要号：4142 研究名称（英文）：A phase 1b/2 study of AK130 (TIGIT/TGF-β bispecific fusion protein) combined with ivonescimab in advanced biliary tract cancer (BTC). 研究名称（中文）：AK130（TIGIT/TGF-β双特异性融合蛋白）联合ivonescimab治疗晚期胆道癌的Ib/II期研究讲者：Haitao Zhao | 北京协和医院报告类型：Poster 摘要号：4152 研究名称（英文）：Envafolimab combined with lenvatinib and gemcitabine plus cisplatin in advanced biliary tract cancer as first-line treatment: A multicenter, single-arm, open-label, phase II study (ENLIGHTEN study). 研究名称（中文）：恩沃利单抗联合仑伐替尼及吉西他滨+顺铂一线治疗晚期胆道癌：多中心、单臂、开放标签、II期研究（ENLIGHTEN研究）讲者：Lixia Xu | 中山大学附属第一医院报告类型：Poster 摘要号：4164 研究名称（英文）：DEB-TACE combined with apatinib and camrelizumab as second-line therapy for unresectable intrahepatic cholangiocarcinoma: A prospective, single-arm, phase II study. 研究名称（中文）：DEB-TACE联合阿帕替尼及卡瑞利珠单抗二线治疗不可切除肝内胆管癌：前瞻性、单臂II期研究讲者：Xuegang Yang | 四川省肿瘤医院报告类型：Poster 摘要号：4236 研究名称（英文）：Donafenib plus immune checkpoint inhibitors with or without oral fluorouracil chemotherapy drugs (S-1/capecitabine) for patients with resected high-risk biliary tract tumor: A multi-center retrospective study. 研究名称（中文）：多纳非尼联合免疫检查点抑制剂±口服氟尿嘧啶类化疗药物（替吉奥/卡培他滨）治疗已切除高危胆道肿瘤：多中心回顾性研究讲者：Huang Huaiyin | 湖南省人民医院报告类型：Poster 胰腺癌摘要号：2509 研究名称（英文）：An investigator-initiated phase I study evaluating the safety, tolerability, and preliminary efficacy of a personalized neoantigen mRNA vaccine (XP-004) combined with PD-1 inhibitor as adjuvant therapy in resected pancreatic cancer patients intolerant to chemotherapy. 研究名称（中文）：由研究者发起的Ⅰ期研究：评估个性化新抗原 mRNA 疫苗（XP-004）联合 PD-1 抑制剂作为辅助治疗，用于根治术后化疗不耐受胰腺癌患者的安全性、耐受性及初步疗效讲者：Wei Wang | 上海鑫谱生物科技有限公司报告类型：Clinical Science Symposium 摘要号：4126 研究名称（英文）：CXCL12+ pericytes as drivers of lymphatic dissemination in pancreatic cancer: Integrated single-cell and spatial analysis. 研究名称（中文）：CXCL12+周细胞作为胰腺癌淋巴转移驱动因素：单细胞及空间整合分析讲者：Xiangxu Wang | 空军军医大学西京医院报告类型：Poster 摘要号：4190 研究名称（英文）：HRS-4642 combined with adebrelimab in previously treated patients with metastatic pancreatic ductal adenocarcinoma. 研究名称（中文）：HRS-4642联合阿得贝利单抗治疗既往经治的转移性胰腺导管腺癌讲者：Xianjun Yu | 复旦大学附属肿瘤医院报告类型：Poster 摘要号：4191 研究名称（英文）：SHR-A2102, a Nectin-4 targeted antibody-drug conjugate, combined with HRS-4642 in previously treated pancreatic ductal adenocarcinoma harboring KRAS G12D mutation. 研究名称（中文）：靶向Nectin-4的抗体药物偶联物SHR-A2102联合HRS-4642治疗既往经治且携带KRAS G12D突变的胰腺导管腺癌讲者：徐近 | 复旦大学附属肿瘤医院报告类型：Poster 摘要号：4198 研究名称（英文）：Surufatinib plus KN046 and chemotherapy as first-line treatment for advanced pancreatic ductal adenocarcinoma: Updated results and biomarker analysis from a phase 1b/2 trial. 研究名称（中文）：索凡替尼联合KN046及化疗一线治疗晚期胰腺导管腺癌：更新结果及生物标志物分析（Ib/II期试验）讲者：Wen-Quan Wang | 复旦大学附属中山医院报告类型：Poster 摘要号：4203 研究名称（英文）：QL1706 combined with nab-paclitaxel and gemcitabine as first-line treatment for locally advanced or metastatic pancreatic adenocarcinoma: A prospective, multicenter, single-arm phase II study. 研究名称（中文）：QL1706联合白蛋白结合型紫杉醇及吉西他滨一线治疗局部晚期或转移性胰腺腺癌：前瞻性、多中心、单臂II期研究讲者：Biyang Cao | 中国医学科学院肿瘤医院报告类型：Poster 摘要号：4209 研究名称（英文）：Efficacy of multimodal thermal therapy combined with immune checkpoint inhibitors and chemotherapy in unresectable pancreatic cancer with liver metastases. 研究名称（中文）：多模式热疗联合免疫检查点抑制剂及化疗治疗不可切除伴肝转移胰腺癌的疗效讲者：Chuntao Wu | 上海交通大学医学院附属上海市第一人民医院报告类型：Poster 摘要号：4224 研究名称（英文）：Phase I clinical trial evaluating dual-targeting CAR-T cells (KD-496) against CLDN18.2 and NKG2DL in advanced gastrointestinal cancers and pancreatic cancers. 研究名称（中文）：靶向CLDN18.2和NKG2DL的双靶向CAR-T细胞（KD-496）治疗晚期胃肠道癌及胰腺癌的I期临床试验讲者：Panpan Zhang | 北京大学肿瘤医院报告类型：Poster 摘要号：4227 研究名称（英文）：Plasma small extracellular vesicle microRNAs as non-invasive biomarkers for the diagnosis of pancreatic ductal adenocarcinoma. 研究名称（中文）：血浆小细胞外囊泡microRNA作为胰腺导管腺癌无创诊断的生物标志物讲者：Yang Yang | 苏州大学附属第三医院报告类型：Poster 摘要号：4231 研究名称（英文）：Safety, efficacy, and immunogenicity of adjuvant therapy with personalized cancer vaccine (PCV) RGL-270 in combination with adebrelimab and mFOLFIRINOX in resectable pancreatic ductal adenocarcinoma (PDAC). 研究名称（中文）：个体化癌症疫苗RGL-270联合阿得贝利单抗及mFOLFIRINOX辅助治疗可切除胰腺导管腺癌的安全性、有效性及免疫原性讲者：Si Shi | 复旦大学附属肿瘤医院报告类型：Poster 备注：排名不分先后，按照摘要号进行排序如有遗漏或任何问题，请给我们留言~ 声明：本文由“肿瘤界”整理与汇编，欢迎分享转载，如需使用本文内容，请务必注明出处。来源：医脉通消化系统肿瘤编辑：Lagertha 审核：阿希雅

ASCO会议临床2期临床结果疫苗临床1期

100 项与白蛋白结合型紫杉醇相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肿瘤	乌拉圭	科兴生物制药股份有限公司	2025-10-31
转移性胰腺癌	秘鲁	浙江海昶生物医药股份有限公司	2025-05-14
胰腺癌	中国	Bristol Myers Squibb Co.	2024-01-05
转移性胰腺腺癌	美国	Teva Pharmaceuticals, Inc.	2023-05-11
不能切除性胰腺癌	日本	Taiho Pharmaceutical Co., Ltd.	2014-12-18
胃癌	日本	Taiho Pharmaceutical Co., Ltd.	2013-02-21
乳腺癌	中国	Abraxis BioScience, Inc.	2008-06-30
非小细胞肺癌	欧盟	Bristol-Myers Squibb Pharma EEIG	2008-01-11
非小细胞肺癌	冰岛	Bristol-Myers Squibb Pharma EEIG	2008-01-11
非小细胞肺癌	列支敦士登	Bristol-Myers Squibb Pharma EEIG	2008-01-11
非小细胞肺癌	挪威	Bristol-Myers Squibb Pharma EEIG	2008-01-11
胰腺腺癌	欧盟	Bristol-Myers Squibb Pharma EEIG	2008-01-11
胰腺腺癌	冰岛	Bristol-Myers Squibb Pharma EEIG	2008-01-11
胰腺腺癌	列支敦士登	Bristol-Myers Squibb Pharma EEIG	2008-01-11
胰腺腺癌	挪威	Bristol-Myers Squibb Pharma EEIG	2008-01-11
转移性乳腺癌	美国	Bristol Myers Squibb Co.	2005-01-07

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期乳腺癌	临床3期	中国	石药集团欧意药业有限公司	2023-04-27
进展期胃腺癌	临床3期	中国	石药集团欧意药业有限公司	2020-03-01
PD-L1阳性三阴性乳腺癌	临床3期	阿根廷	Hoffmann-La Roche, Inc.	2019-12-10
PD-L1阳性三阴性乳腺癌	临床3期	智利	Hoffmann-La Roche, Inc.	2019-12-10
PD-L1阳性三阴性乳腺癌	临床3期	捷克	Hoffmann-La Roche, Inc.	2019-12-10
PD-L1阳性三阴性乳腺癌	临床3期	法国	Hoffmann-La Roche, Inc.	2019-12-10
PD-L1阳性三阴性乳腺癌	临床3期	匈牙利	Hoffmann-La Roche, Inc.	2019-12-10
PD-L1阳性三阴性乳腺癌	临床3期	意大利	Hoffmann-La Roche, Inc.	2019-12-10
PD-L1阳性三阴性乳腺癌	临床3期	墨西哥	Hoffmann-La Roche, Inc.	2019-12-10
PD-L1阳性三阴性乳腺癌	临床3期	秘鲁	Hoffmann-La Roche, Inc.	2019-12-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03915444 (CTgov)	临床2期	转移性胰腺腺癌 \| 胰腺导管腺癌 \| 转移性胰腺导管腺癌	42	NS+nab-Paclitaxel+gemcitabine+Cisplatin	製蓋簾選窪簾遞糧鏇製 = 憲積網餘蓋積築齋選膚鑰蓋選簾顧憲鏇獵積壓 (壓憲製鏇齋蓋鏇齋糧鹹, 繭蓋憲齋鏇構壓繭積餘 ~ 齋網願膚醖齋遞顧餘範) 更多	-	2026-04-23
NCT03138720 (CTgov)	临床2期	胰腺腺癌 \| 胰腺导管腺癌 \| 不能切除性胰腺癌 ... 更多	40	Paclitaxel Protein Bound (Abraxane) (Cohort A: Resectable)	獵簾範觸築築餘繭廠醖 = 積範觸襯壓憲廠鹽鑰鏇鹽鑰蓋窪憲選窪鹹遞築 (壓鹽鹽網齋製願蓋齋壓, 夢齋衊窪構衊艱鹽觸窪 ~ 夢鬱衊製醖遞範簾範憲) 更多	-	2026-04-22
NCT03138720 (CTgov)	临床2期	胰腺腺癌 \| 胰腺导管腺癌 \| 不能切除性胰腺癌 ... 更多	40	Paclitaxel Protein Bound (Abraxane) (Cohort B: Borderline Resectable/Locally Advanced (Unresectable))	獵簾範觸築築餘繭廠醖 = 衊窪廠齋蓋鹽鹹醖顧鏇鹽鑰蓋窪憲選窪鹹遞築 (壓鹽鹽網齋製願蓋齋壓, 鏇範遞廠醖範範蓋艱壓 ~ 窪遞遞襯構齋淵衊積鏇) 更多	-	2026-04-22
NCT05494866 (IntenSify, AACR2026)	临床1期	胰腺癌 CYP3A5 expression	6	nab-paclitaxel+gemcitabine+cobicistat (Metastatic Pancreatic Cancer)	夢網願醖築鹽簾蓋鑰鹽(蓋積鬱願艱製襯襯憲製) = One patient was hospitalized after 6 weeks of treatment for grade 4 acute respiratory distress syndrome associated with LDH increase and lung ground-glass opacity in the CT scan. Two more asymptomatic cases of ground glass opacity associated with LDH increase were observed. 餘鬱衊範壓膚齋襯鹽製 (築餘築齋觸構鬱網壓膚 )	不佳	2026-04-21
SWOG S0819 (AACR2026)	临床3期	非小细胞肺癌 Serial CTRS	1,275	Cetuximab + carboplatin/paclitaxel	憲淵網網齋鏇鏇積獵衊(遞選醖廠衊鏇夢鑰鬱鹽) = BOR achieved 35% (33–37%) power 衊簾衊鹹餘廠築淵選憲 (鑰蓋艱鬱窪壓觸膚糧範 ) 更多	积极	2026-04-20
SWOG S0819 (AACR2026)	临床3期	非小细胞肺癌 Serial CTRS	1,275	Bevacizumab + cetuximab + carboplatin/paclitaxel		积极	2026-04-20
NCT05257408 (ROSELLA, Pubmed \| Lancet)	临床3期	铂耐药性卵巢癌	381	Relacorilant + Nab-paclitaxel	膚顧鹹醖鹽簾製鬱壓選(壓衊餘鹽醖鹹艱艱衊鏇) = Neutropenia (121 [64%]), anaemia (115 [61%]), fatigue (101 [54%]), and nausea (82 [44%]) were the most common adverse events in the relacorilant combination group. 膚艱構壓窪廠網構顧襯 (憲齋鹹蓋憲網廠膚夢鬱 )	积极	2026-04-01
NCT05257408 (ROSELLA, Pubmed \| Lancet)	临床3期	铂耐药性卵巢癌	381	Nab-paclitaxel		积极	2026-04-01
ROSELLA (ESGO2026)	临床3期	铂耐药性卵巢癌	234	Relacorilant + nab-paclitaxel	窪繭鑰衊廠齋壓齋構憲(鹽築簾願製膚襯糧繭鑰) = 鹹糧淵糧襯壓構顧積醖獵遞鑰築糧選獵繭襯遞 (夢積憲憲齋淵觸網構醖, 5.38 ~ 9.53) 更多	积极	2026-02-28
ROSELLA (ESGO2026)	临床3期	铂耐药性卵巢癌	234	nab-paclitaxel	壓淵窪築鬱齋觸窪醖齋(艱衊鹹醖鏇壓窪壓鏇鏇) = 襯簾繭製淵齋網窪顧衊鑰鹹艱衊範襯蓋鬱夢鑰 (簾窪繭醖網淵簾艱遞鑰 ) 更多	积极	2026-02-28
INTERLACE (ESGO2026)	N/A	局部晚期宫颈癌	32	CarboplatinCisplatinin + Paclitaxel + CarboplatinCisplatinPaclitaxel	遞醖鬱選鹹獵艱憲鬱觸(襯淵襯構衊壓獵鹽築積) = 鏇獵網艱構網簾壓鏇簾網鏇製觸廠襯鹽築選網 (範鏇膚繭憲繭選淵壓衊 )	积极	2026-02-28
ESGO2026	N/A	子宫内膜癌辅助	63	Carboplatin with paclitaxel (CP)	憲淵膚餘夢積網積醖廠(蓋願獵壓築糧網醖壓獵) = 艱膚窪簾襯簾衊鏇衊餘鑰網鑰願積夢製鹹製艱 (築顧憲襯憲鹽襯夢蓋鏇 ) 更多	积极	2026-02-28
ESGO2026	N/A	子宫内膜癌	36	Weekly carboplatin-paclitaxel (TC) (Frail patients unsuitable for 3-weekly chemotherapy)	顧願鏇壓襯壓膚艱鏇壓(齋網觸憲範鹹鹹壓積範) = Weekly TC was overall well tolerated, with low rates of neutropenia(11%), anaemia(22%), thrombocytopenia(3%), fatigue(6%), neurotoxicity(8%) and gastrointestinal toxicity(3%), and no cutaneous events 蓋顧蓋襯製窪蓋壓範築 (襯鏇壓獵範築製憲廠鑰 )	积极	2026-02-28
ESGO2026	N/A	卵巢癌	95	carboplatin-paclitaxel chemotherapy	窪選鏇製淵憲壓鹹憲艱(衊糧鑰顧網衊鹽製壓蓋) = 鏇鬱鏇窪淵鹹簾鏇衊鬱廠遞壓積廠選鹽網艱餘 (蓋襯遞壓鑰簾餘廠簾簾, 6 ~ 12)	积极	2026-02-28